Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (93)	2/15/2001 2:53:10 AM
From: JFitnich	Read Replies (1) \| Respond to of 598

My notes from the CCall this afternoon. Nothing new and nothing different from what was presented at H&Q from what I heard.  4 Drugs in clinic - Up from 1 last year.  58 targets with 20 leads against these targets. All leads by gene expression. Goeddel said later in the Q & A that TLRK has so many leads that they will only be looking at their top 20 from a resource standpoint.  5 Leads are advanced. Inflammation, immune disorders, bacteria (?), lipid disorders, and diabetes.  1-2 IND's per year for next several years.  They have $75M in funding from Japan Tobacco through 2004.  Expect 1 more strategic collaboration this year.  They expect to initiate registration studies with T-67 by end of this year. Q&A  Tony Butler from Lehman asked about the press release in January regarding the finding of 10 new oncogenes. (Post holiday stupor?…I missed this one). Goeddel said that in the last 6-8 months, using microarray technology and looking at various cancer tissue samples they have found at least 10 of these oncogenes. Butler thought this was a "robust" number.  Thomas Weisel - Missed the analyst's name- Asked which of the 5 advance leads would get to trials first - Goeddel said that in 2 years all 5 would most likely be in trials, although inflammation, immune disorders, and diabetes seemed more advanced than the others. All systems seem to be firing from a clinical and science standpoint. Now we'll see if the stock is able to hold in terms of valuation. Jason